Mild Persistent Asthma, Uncomplicated Clinical Trial
The purpose of this study is to test the hypothesis that 18—22 week treatment with the inverse agonist nadolol will improve airway hyperresponsiveness in patients with mild asthma, compared to placebo.
| Status | Active, not recruiting |
| Enrollment | 60 |
| Est. completion date | |
| Est. primary completion date | May 2016 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 60 Years |
| Eligibility |
Inclusion Criteria: Individuals who meet all of the following criteria are eligible for enrollment as study participants: 1. Males and females with physician-diagnosed asthma between the ages of 18- 60. 2. Pre-bronchodilator FEV1 80% or greater than the predicted value 3. Baseline PC20 (based on FEV1) = 4 mg/ml on methacholine challenge test. 4. Asthma Control Questionnaire Score (ACQ) <1.25 5. Baseline blood pressure = 110/65mm Hg 6. Baseline pulse rate = 60 beats/min. 7. Never-smoker or former-smoker < 10 pack.year and has not smoked within 1 year. 8. Able to complete diary cards and comply with study procedures. 9. Females of childbearing age may participate only if they have a negative pregnancy test, are non-lactating, and agree to practice an adequate birth control method (abstinence, combination barrier and spermicide, or hormonal) for the duration of the study. Exclusion Criteria: Subjects who meet ANY of the following criteria are not eligible for enrollment: 1. Inability or unwillingness of the participant to give written informed consent 2. History of upper/lower respiratory tract infection or asthma exacerbation requiring systemic steroids within 6 weeks of Visit 1 3. Use of rescue medication (e.g., albuterol) more than twice per week during the week preceding Visit 1 excluding the use of such medication as preventative prior to exercise. 4. History of hospitalization for asthma in the preceding year 5. History of intubation for asthma 6. Currently diagnosed with chronic obstructive pulmonary disease (COPD) 7. Currently taking any beta-blocker medication 8. History of adverse reaction or allergy to any beta-blocker medication 9. History of neurological, hepatic, renal, or other medical conditions that may interfere with the interpretation of data or the patient's participation in the study or may increase safety concerns 10. Current diabetes or hyperthyroidism 11. History of cardiovascular diseases including uncontrolled hypertension (BP >160/100), ischemic heart disease, congestive heart failure, valvular heart disease or cardiomyopathy 12. Known allergy or sensitivity to atropine or ipratropium bromide 13. Abnormal entry laboratory values at baseline except for the following tests, where values outside the normal limits will be acceptable as follows: Hct = 30%, platelet count > 100,000, ALT and AST < 1.5 x upper normal limit 14. Known bleeding disorders, platelet count <100,000, PT or PTT > 1.5 x normal control (if participating in bronchoscopy sub-study) 15. Known allergy to lidocaine (if participating in bronchoscopy sub-study) 16. Documented or self-reported current history of alcoholism or drug abuse 17. Participation in another research trial within 30 days of starting this trial 18. Unwillingness or inability to comply with study procedures 19. Inability to swallow the study medication capsule 20. Use of any exclusion medication within the time period specified 21. Pregnant or nursing 22. Receiving allergen immunotherapy (desensitization injections) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | Duke University Medical Center | Durham | North Carolina |
| United States | Baylor College of Medicine | Houston | Texas |
| United States | Washington University School of Medicine | St. Louis | Missouri |
| Lead Sponsor | Collaborator |
|---|---|
| Invion, Inc. |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The change in methacholine provocative concentration causing a 20% fall (PC20) based on forced expiratory volume in 1 second (FEV1) between baseline visit and final dose dispensing visit. | 4 months | No |